Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.34 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22255172 | 0.78 | LMNA (0.34) | MAPTLMNAKDM4EHTTSMN1; SMN2 | |
| SCHEMBL24309186 | 0.73 | LMNA (0.40) | TLR8MAPTLMNAKDM4EHTT | |
| SCHEMBL21210598 | 0.73 | LMNA (0.40) | TLR8MAPTLMNAKDM4EHTT | |
| SCHEMBL24253246 | 0.73 | CYP19A1 (0.35) | KDM4EHTT | |
| SCHEMBL24253278 | 0.73 | ADA (0.32) | MAPT | |
| SCHEMBL24253461 | 0.73 | NPC1 (0.39) | KCNH2SMN1; SMN2 | |
| SCHEMBL22272579 | 0.72 | IDH1 (0.43) | IDH1IDH2PRMT6MAPTLMNA | |
| SCHEMBL1767640 | 0.71 | LMNA (0.40) | IDH1IDH2TLR8MAPTLMNA | |
| SCHEMBL20898646 | 0.71 | ADA (0.36) | TLR8MAPTLMNA | |
| SCHEMBL21166123 | 0.68 | IDH1 (0.38) | IDH1IDH2PRMT6MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | IDH1 3309/4885IDH2 4024/4885TLR8 4797/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | IDH1 3309/4885IDH2 4024/4885TLR8 4797/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | IDH1 3309/4885IDH2 4024/4885TLR8 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.